DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

NCT03255083 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

13

Enrollment

INDUSTRY

Sponsor class

Stopped This study was terminated based on a business decision by the Sponsor.

Conditions

Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG: DS-1205c
DRUG: Osimertinib

Sponsor

Daiichi Sankyo